SCHEMBL514352

SCHEMBL514352

COC(=O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.64
CA2 P00918 2/20 0.64
MAPT P10636 3/20 0.58
MRGPRX4 Q96LA9 1/20 0.57
EPHX2 P34913 4/20 0.56
TRPV1 Q8NER1 3/20 0.55
TDP1 Q9NUW8 1/20 0.55
CA12 O43570 1/20 0.55
CA7 P43166 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
FAAH O00519 2/20 0.54
RAB9A P51151 2/20 0.54
NPC1 O15118 1/20 0.54
TP53 P04637 1/20 0.54
HPGD P15428 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
STS P08842 1/20 0.53
HDAC3 O15379 1/20 0.53
HDAC1 Q13547 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14930553 0.94 CA1 (0.58) CA1CA2MAPTMRGPRX4EPHX2
SCHEMBL508309 0.90 MAPT (0.57) CA1CA2MAPTMRGPRX4EPHX2
SCHEMBL508310 0.90 MAPT (0.57) CA1CA2MAPTMRGPRX4EPHX2
SCHEMBL508864 0.90 MRGPRX4 (0.57) CA1CA2MAPTMRGPRX4EPHX2
SCHEMBL934140 0.89 CA1 (0.60) CA1CA2MAPTMRGPRX4TRPV1
SCHEMBL28050325 0.89 CA1 (0.60) CA1CA2MAPTMRGPRX4EPHX2
SCHEMBL22721357 0.86 MRGPRX4 (0.71) MAPTMRGPRX4RAB9ANPC1SMN1; SMN2
SCHEMBL9172082 0.85 TRPV1 (0.58) CA1CA2MAPTMRGPRX4EPHX2
SCHEMBL5325355 0.85 CA1 (0.56) CA1CA2MAPTMRGPRX4EPHX2
SCHEMBL20805840 0.84 EPHX2 (0.77) MAPTEPHX2TRPV1FAAHRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 US disclosed
WO-2025090727-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2025-05-01 WO disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
US-11760701-B2 Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK (US) 2023-09-19 US disclosed
US-11760701-B2 Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK (US) 2023-09-19 US disclosed
WO-2023101256-A1 5-ALPHA-REDUCTASE INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF 주식회사 팜어스바이오사이언스 2023-06-08 WO disclosed
US-20230065629-A1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-03-02 US disclosed
US-20090215825-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME LLC 2009-08-27 US disclosed
US-7572922-B2 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK & CO., INC. (US) 2009-08-11 US disclosed
US-20070043011-A1 Substituted benzanilide compound and noxious organism controlling agent MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-02-22 US disclosed
EP-1671941-A1 SUBSTITUTED BENZANILIDE COMPOUND AND PEST CONTROL AGENT Nissan Chemical Industries, Ltd. (JP) 2006-06-21 EP disclosed
US-20060084681-A1 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK SHARP & DOHME LLC 2006-04-20 US disclosed
EP-1590336-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2005-11-02 EP disclosed
EP-1517881-A1 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES Syngenta Participations AG (CH) 2005-03-30 EP disclosed
WO-2004069158-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2004-08-19 WO disclosed
WO-2004002943-A1 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2004-01-08 WO disclosed
US-20030119816-A1 Flavone derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215825-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE GLP1R, GCGR, GPR119 CA1 2857/4885CA2 1262/4885MAPT 4651/4885
US-20060084681-A1 Substituted pyrazoles, compositions containing such compounds and methods of use GLP1R, GCGR, GPR119 CA1 2857/4885CA2 1262/4885MAPT 4651/4885
US-20030119816-A1 Flavone derivatives, preparation method and use as medicines REN, CYP2F1, CYP3A43 CA1 3975/4885CA2 818/4885MAPT 3647/4885
US-20070043011-A1 Substituted benzanilide compound and noxious organism controlling agent L3MBTL1, L3MBTL3, L3MBTL4 CA1 975/4885CA2 144/4885MAPT 4655/4885
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 CA1 4288/4885CA2 4468/4885MAPT 3248/4885
US-11760701-B2 Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same AFF2, AFF4, AFF1 CA1 3362/4885CA2 4213/4885MAPT 2445/4885
US-20230065629-A1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF REN, ATP6V1B1, GLS CA1 4867/4885CA2 4613/4885MAPT 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.